TTrialPathMatch Me to Trials
← Back to trials
RecruitingNon-small Cell Lung Cancer (NSCLC)

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Eligible age

18+ yrs

Accepts

All genders

Locations

19 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb

You may qualify if…

  • ✓ Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease.
  • ✓ Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
  • ✓ Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
  • ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.

You may not qualify if…

  • ✕ Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements.
  • ✕ Participants must not have an active autoimmune disease.
  • ✕ Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, major thrombotic or embolic events or major hemorrhagic events within 6 months prior to randomization, or significant risk of pulmonary hemorrhage.
  • ✕ Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ Grade 2), or current or suspected ILD or pneumonitis.
  • ✕ Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease.
  • ✕ Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's recruiting

Alabama

Daphne

Colorado

Golden

Delaware

Newark

Florida

Ocala · Tamarac

Georgia

Marietta

Illinois

Chicago · Evanston · Peoria

Indiana

Fort Wayne

Kentucky

Lexington

Michigan

Detroit

Minnesota

Maple Grove · Minneapolis

Missouri

Columbia

Source: ClinicalTrials.gov · NCT07361497 · last updated 2026-11-05

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent C · TrialPath